Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032670 | 0.92 | MAPT (0.37) | ALKMEN1KMT2AGAAMAPT | |
| SCHEMBL1009767 | 0.91 | CDK4 (0.36) | ALKMEN1KMT2AGAAMAPT | |
| SCHEMBL8513625 | 0.89 | MEN1 (0.43) | MEN1KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL26452409 | 0.89 | ALK (0.35) | ALKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23572603 | 0.85 | PPM1A (0.37) | ALKMEN1KMT2AGAAMAPT | |
| SCHEMBL30104206 | 0.85 | PPM1A (0.37) | ALKMEN1KMT2AGAAMAPT | |
| SCHEMBL9898823 | 0.85 | CDK4 (0.36) | ALKMEN1KMT2AGAAMAPT | |
| SCHEMBL12424597 | 0.84 | PDK2 (0.42) | MEN1KMT2AGAAALDH1A1PDK2 | |
| SCHEMBL9932428 | 0.83 | MEN1 (0.43) | MEN1KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL1813707 | 0.82 | MEN1 (0.42) | MEN1KMT2AGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230133211-A1 | PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4108735-A1 | PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING SAID PHOTOCHROMIC CYCLIC COMPOUND | Tokuyama Corporation (JP) | 2022-12-28 | — | — | EP | disclosed |
| EP-4047030-A1 | PHOTOCHROMIC HYDROXYURETHANE COMPOUND | Tokuyama Corporation (JP) | 2022-08-24 | — | — | EP | disclosed |
| US-20220137262-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS | JOHNSON & JOHNSON VISION CARE (US) | 2022-05-05 | — | — | US | disclosed |
| US-11256002-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3633423-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS | Johnson & Johnson Vision Care, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-104898187-B | Ophthalmic devices comprising photochromic materials having reactive substituents | INNOTECH, INC., JOHNSON AND JOHNSON VISION CARE (US) | 2019-12-10 | — | — | CN | disclosed |
| EP-1872159-B1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS | JOHNSON AND JOHNSON VISION CARE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190129067-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS | JOHNSON & JOHNSON VISION CARE (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2006110306-A1 | PHOTOCHROMIC CONTACT LENSES AND METHODS FOR THEIR PRODUCTION | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110513-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110520-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110221-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110219-A1 | PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS | TRANSITIONS OPTICAL, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060226401-A1 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. | 2006-10-12 | — | — | US | disclosed |
| US-20060226400-A1 | Photochromic materials with reactive substituents | TRANSITIONS OPTICAL LIMITED (IE) | 2006-10-12 | — | — | US | disclosed |
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. | 2006-10-12 | — | — | US | disclosed |
| US-20060226402-A1 | Ophthalmic devices comprising photochromic materials having extended PI-conjugated systems | KIM BEON-KYU | 2006-10-12 | — | — | US | disclosed |
| US-20050258408-A1 | Photochromic contact lenses and methods for their production | MOLOCK FRANK F | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | INCENP, PCNA, INTS6 | ALK 2838/4885MEN1 3210/4885KMT2A 1342/4885 |
| US-20230133211-A1 | PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND | CRY1, CCNL2, CCNT1 | ALK 4737/4885MEN1 847/4885KMT2A 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.